Fast Locator 2011-2012: PharmaCore, Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: PharmaCore, Inc.


Since 2000, PharmaCore has performed a variety of chemistry services for leading pharmaceutical and biotechnology companies including: custom organic synthesis; cGMP scale-up; development of novel molecular building blocks; chemical process research and development; and medicinal chemistry services.

Custom Organic Synthesis
Custom organic synthesis is one of the things PharmaCore does best.

PharmaCore’s chemists can synthesize new compounds rapidly, keeping your research on track. For the large pharmaceutical company, that means supplementing your world-class research programs. For smaller companies, PharmaCore can serve as your off-site “chemistry department.”

With increasing dependence of the industry on outsourcing synthetic chemistry, large pharmaceutical companies and emerging drug discovery companies come to PharmaCore to turn multiple synthesis steps with marginal yields into practical chemistry with higher yields.

GMP Manufacturing
PharmaCore has developed an outstanding state-of-the-art facility to serve the growing need for GMP clinical material and bulk active pharmaceutical ingredients (APIs) accompanying the rapid pace of drug discovery.

PharmaCore's new GMP manufacturing facility features five new production suites. The plant is designed with maximum versatility with process conditions of -70 to 160+°, glass and Hastelloy, computer monitoring and flexible equipment configurations. Reactors with process volumes from 2000 liters to laboratory scale are ready to supply your clinical needs.

GMP Analytical
PharmaCore's new GMP analytical laboratories are equipped with the most up-to-date instrumentation to serve your analytical needs, including ICH Q1A-compliant stability chambers. Our services include: analytical methods development/validation/transfer; analytical methods improvement; ICH stability studies, storage and testing; reference standard qualification; and product release/retain. Our seasoned team of scientists brings a wealth of pharmaceutical industry experience to your project.


Our continued success is due to our competitive pricing, our unwavering commitment to customer service and to the talent and experience of our scientists.


Regions where services are provided:

North America, Europe, Asia (global)


Outsourcing serivces provided:

Development and Phase I/IICTM

  • Process development-small molecule

Commercial Manufacturing

  • API and advanced intermediates (GMP, small molecules)

Analytical Services

  • Chemistry and stability

API Production Technologies

  • Acetylenic chemistry
  • Acid chlorides
  • Acylation
  • Amidation
  • Amino acids and analogs
  • Azide chemistry
  • Borane chemistry
  • Bromine chemistry/bromination
  • Carbohydrate chemistry
  • Heterocyclic chemistry
  • Fluorination
  • Hydrazine chemistry
  • Nitration
  • Organometallic chemistry
  • Phosgenation
  • Sulfonation

Website:

www.pharmacore.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here